Spark Therapeutics Inc (NASDAQ:ONCE) shares traded down 0% on Tuesday . The stock traded as low as $50.06 and last traded at $50.23. 1,442,221 shares traded hands during trading, an increase of 87% from the average session volume of 772,221 shares. The stock had previously closed at $50.23.
Several research analysts recently weighed in on the company. Wedbush upgraded Spark Therapeutics from an “underperform” rating to a “neutral” rating and dropped their target price for the stock from $65.00 to $50.00 in a research note on Tuesday, December 12th. They noted that the move was a valuation call. Mizuho restated a “buy” rating and set a $79.00 target price on shares of Spark Therapeutics in a research note on Wednesday. BMO Capital Markets set a $64.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a research note on Wednesday. Raymond James Financial set a $66.00 price target on Spark Therapeutics and gave the stock a “buy” rating in a research report on Wednesday. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $64.00 price target (down previously from $73.00) on shares of Spark Therapeutics in a research report on Wednesday. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and seventeen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $69.88.
The stock has a market capitalization of $1,858.78, a price-to-earnings ratio of -6.64 and a beta of 3.02.
In other Spark Therapeutics news, insider Katherine A. High sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total transaction of $356,600.00. Following the completion of the sale, the insider now directly owns 215,000 shares in the company, valued at approximately $15,333,800. The transaction was disclosed in a document filed with the SEC, which is available through this link. 7.30% of the stock is currently owned by insiders.
Hedge funds have recently bought and sold shares of the company. Gilder Gagnon Howe & Co. LLC purchased a new position in Spark Therapeutics in the fourth quarter worth approximately $28,188,000. Orbimed Advisors LLC purchased a new position in Spark Therapeutics in the third quarter worth approximately $38,340,000. Rockefeller Financial Services Inc. grew its position in Spark Therapeutics by 27,905.0% in the fourth quarter. Rockefeller Financial Services Inc. now owns 353,983 shares of the biotechnology company’s stock worth $18,202,000 after acquiring an additional 352,719 shares during the period. Jennison Associates LLC purchased a new position in Spark Therapeutics in the third quarter worth approximately $27,239,000. Finally, JPMorgan Chase & Co. grew its position in Spark Therapeutics by 15.0% in the third quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after acquiring an additional 241,016 shares during the period.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.